GlassScriptPhysician profile
Suzanne A Mains
NPI 1619261542
$5,095.85
in general payments reported to CMS, 2019-2025
30 companies · $1,546 in 2025
The $1,546 reported for 2025 was more than what 91% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $475 · 2022: $743 · 2023: $1,079 · 2024: $1,252 · 2025: $1,546.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,877.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,877.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $790.67 | 2023-2025 | Gemtesa, Orgovyx |
| Abbvie INC. | $548.64 | 2021-2025 | |
| Janssen Biotech, INC. | $501.74 | 2024-2025 | Erleada, Akeega, Carvykti |
| Astellas Pharma US INC | $485.95 | 2021-2025 | Xtandi, Myrbetriq |
| Antares Pharma, INC. | $403.19 | 2021-2025 | Xyosted, Tlando, Nocdurna |
| 180 Medical, INC. | $230.78 | 2021-2025 | Gentlecath |
| Merck Sharp & Dohme LLC | $225.70 | 2022-2025 | Lynparza, Keytruda, Welireg |
| Halozyme INC | $220.12 | 2023 | |
| Urogen Pharma, INC. | $216.53 | 2022-2025 | Jelmyto |
| Myriad Genetic Laboratories, INC. | $215.32 | 2021-2024 | Myrisk, Prolaris |
| Boston Scientific Corporation | $191.27 | 2024-2025 | Ams 700, Spaceoar Vue System - 10ml, Rezum Generator |
| Pfizer INC. | $178.37 | 2021-2024 | |
| Urovant Sciences INC | $128.18 | 2022 | |
| Tolmar, INC. | $127.04 | 2023-2025 | Jatenzo, Eligard |
| Ferring Pharmaceuticals INC. | $123.39 | 2024-2025 | Adstiladrin |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $82.52 | 2025 | Givlaari |
| Mission Pharmacal Company | $59.04 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $55.07 | 2024-2025 | |
| Endo USA, INC. | $53.71 | 2025 | Aveed, Xiaflex |
| Endo Pharmaceuticals INC. | $44.62 | 2022-2023 | Aveed, Xiaflex |
| Hollister Incorporated | $35.86 | 2021-2022 | |
| Tempus Ai, INC | $29.63 | 2025 | Xt Cdx |
| Allergan, INC. | $21.33 | 2021 | |
| Tolmar Pharmaceuticals, INC. | $20.33 | 2021 | |
| Blue Earth Diagnostics | $19.68 | 2021 | |
| Axonics, INC. | $18.32 | 2024 | Axonics |
| Novo Nordisk INC | $18.26 | 2024 | Wegovy |
| Coloplast Corp | $17.78 | 2023 | Speedicath |
| Rochester Medical Corporation | $16.49 | 2022 | |
| Dentsply Ih Ab | $16.32 | 2025 | Lofric |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suzanne Mains listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.